•
Mar 28
Danaher Q1 2025 Earnings Report
Danaher reported stable revenue and stronger-than-expected earnings and cash flow in Q1 2025.
Key Takeaways
Danaher’s Q1 2025 performance exceeded expectations, with net income reaching nearly $1 billion, flat core revenue, and continued strength in bioprocessing and diagnostics segments.
Net income was $954 million with diluted EPS of $1.32 and adjusted EPS of $1.88.
Revenue declined 1.0% year-over-year to $5.741 billion.
Free cash flow came in at $1.06 billion.
Core revenue remained flat compared to the same quarter last year.
Danaher
Danaher
Danaher Revenue by Segment
Forward Guidance
Danaher expects low single-digit core revenue growth in Q2 2025 and maintains its full-year outlook with 3% core revenue growth and adjusted EPS between $7.60 and $7.75.
Positive Outlook
- Momentum continues in bioprocessing.
- Better-than-expected respiratory demand supports diagnostics.
- Danaher Business System (DBS) continues to drive productivity gains.
- Strong balance sheet supports resilience.
- Innovation and market share gains expected to continue.
Challenges Ahead
- Revenue remains flat YoY, with pressure in diagnostics and life sciences.
- Macroeconomic backdrop becoming more dynamic.
- Lower cash flow compared to the previous year.
- No geographic breakdown or growth detail provided.
- Continued headwinds in parts of the diagnostics segment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income